PRECISE建议用于前列腺癌主动监测患者前列腺MRI:一项批判性综述
PRECISE建议于2016年发布,旨在标准化主动监测前列腺癌患者MRI评估疾病进展的报告。现有研究显示PRECISE预测进展的汇总阴性预测值高但汇总阳性预测值低。本文基于两所教学医院的使用经验,批判性评价PRECISE的优缺点并提出改进方向。
要点
- PRECISE预测进展的汇总阴性预测值高但汇总阳性预测值低。
- 应用PRECISE评分时需考虑图像质量。
- 建议采用PRECISE 3F亚类标记未达显著标准的进展。
核心结论
- PRECISE在临床实践中应用存在需澄清的问题,作者基于两所教学医院经验提出改进建议包括考虑图像质量、引入定量阈值、采用PRECISE 3F亚类及与基线和最近一次既往检查比较。
研究设计与样本
- 临床观点文章,基于两所教学医院使用PRECISE的临床实践经验进行批判性评价。
诊断标准与关键数值
- 现有研究显示PRECISE预测进展的汇总阴性预测值高但汇总阳性预测值低。
临床应用与阅片要点
- 应用PRECISE评分时应考虑图像质量。
- 作者建议纳入疾病进展的定量阈值。
- 作者建议采用PRECISE 3F亚类标记未达显著标准的进展。
- 作者建议与基线和最近一次既往检查进行比较。
- 需澄清的问题包括多病灶患者患者层面评分的推导、PRECISE 5分的预期应用(即是否要求疾病发展至不再局限于器官)以及既往MRI不可见病变患者中新病灶的分类。
局限性
- 现有报告PRECISE临床实践结局的研究数量有限。
- PRECISE预测进展的汇总阳性预测值低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) recommendations were published in 2016 to standardize the reporting of MRI examinations performed to assess for disease progression in patients on active surveillance for prostate cancer. Although a limited number of studies have reported outcomes from use of PRECISE in clinical practice, the available studies have demonstrated PRECISE to have high pooled NPV but low pooled PPV for predicting progression. Our experience in using PRECISE in clinical practice at two teaching hospitals has highlighted issues with its application and areas requiring clarification. This Clinical Perspective critically appraises PRECISE on the basis of this experience, focusing on the system's key advantages and disadvantages and exploring potential changes to improve the system's utility. These changes include consideration of image quality when applying PRECISE scoring, incorporation of quantitative thresholds for disease progression, adoption of a PRECISE 3F sub-category for progression not qualifying as substantial, and comparisons with both the baseline and most recent prior examinations. Items requiring clarification include derivation of a patient-level score in patients with multiple lesions, intended application of PRECISE score 5 (i.e., if requiring development of disease that is no longer organ-confined), and categorization of new lesions in patients with prior MRI-invisible disease.
引用
- Sanmugalingam, Sushentsev, Lee, et al. The PRECISE Recommendations for Prostate MRI in Patients on Active Surveillance for Prostate Cancer: A Critical Review. AJR Am J Roentgenol. 2023. PMID: 37341180. doi:10.2214/AJR.23.29518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。